Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 3, 1997, Pages 529-532

  Segura, A M ^a   Gutierrez O ^b   Otero, W ^b   Angel, A ^b   Genta, R M ^a   Graham, D Y ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; FURAZOLIDONE; METRONIDAZOLE; UREA;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; COLOMBIA; DEVELOPING COUNTRY; DIARRHEA; DRUG EFFICACY; ENDOSCOPY; FATIGUE; FEMALE; GRAM NEGATIVE INFECTION; HEADACHE; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MALE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; STOMACH BIOPSY; VERTIGO; VOMITING;

EID: 0030851613     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00172.x     Document Type: Article

References (37)

1. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-91.
2. van der Hulst RWM, Keller JJ, Rauws EA, Tytgat GNJ. Treatment of Helicobacter pylori infection in humans: a review of the world literature. Helicobacter 1996; 1: 6-19.
3. Thijs JC, van Zwet AA, Moolenaar W, Wolfhagen MJ, ten Bokkel Huinink J. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects. Am J Gastroenterol 1996; 91: 93-7.
4. Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. J Am Med Assoc 1996; 275: 622-9.
5. Bell GD, Powell K, Burridge SM, et al. Experience with 'triple' anti-Helicobacter pylori eradication therapy: side-effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992; 6: 427-35.
6. oach LA, Langenberg WL, Bertola MA, Dankert J, Tytgat GN. Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis 1994; 26: 321-7.
7. Parasakthi N, Goh KL. Metronidazole resistance among Helicobacter pylori strains in Malaysia. Am J Gastroenterol 1992; 87: 808(Letter).
8. Queiroz DM, Coimbra RS, Mendes EN, et al. Metronidazole-resistant Helicobacter pylori in a developing country. Am J Gastroenterol 1993; 88: 322-3(Letter).
9. Rautelin H, Seppala K, Renkonen OV, Vainio U, Kosunen TU. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother 1992; 36: 163-6.
10. Xia HX, Daw MA, Beattie S, Keane CT, O'Morain CA. Prevalence of metronidazole-resistant Helicobacter pylori in dyspeptic patients. Irish J Med Sci 1993; 162: 91-4.
11. Banatvala N, Davies GR, Abdi Y, et al. High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut 1994; 35: 1562-6.
12. Al-Assi MT, Ramirez FC, Lew GM, Genta RM, Graham DY. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. Am J Gastroenterol 1994; 89: 1203-5.
13. Reddy R, Osato M, Gutierrez O, Kim JG, Graham DY. Metronidazole resistance is high in Korea and Colombia and appears to be rapidly increasing in the U.S. Gastroenterology 1996; 110: A238(Abstract).
14. Howden A, Boswell P, Tovey F. In vitro sensitivity of Campylobacter pyloridis to furazolidone. Lancet 1986; 2: 1035 (Letter).
15. Graham DY, Klein PD, Opekun AR, et al. In vivo susceptibility of Campylobacter pylori. Am J Gastroenterol 1989; 84: 233-8.
16. Genta RM, Robason GO, Graham DY. Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Hum Pathol 1994; 25: 221-6.
17. Fagan T. Quickbasic program for exact and mid-P confidence intervals for a binomial proportion. Comput Biol Med 1996; 26: 263-7.
18. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. J Am Med Assoc 1994; 272: 65-9.
19. Graham DY. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med 1993; 328: 349-50.
20. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 61: Schistosomes, liver flukes and Helicobacter pylori. Lyon, France: International Agency for Research on Cancer, 1994.
21. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-40.
22. Graham DY. Benefits from elimination of Helicobacter pylori infection include major reduction in the incidence of peptic ulcer disease, gastric cancer, and primary gastric lymphoma. Prev Med 1994; 23: 712-6.
23. Graham DY, de Boer WA, Tytgat GN. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 1996; 91: 1072-6.
24. Coelho LG, Passos MC, Chausson Y, et al. Duodenal ulcer and eradication of Helicobacter pylori in a developing country. An 18-month follow-up study. Scand J Gastroenterol 1992; 27: 362-6.
25. Coelho LG, Passos MC, Chausson Y, Castro L. Five-day bismuth-free triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse. Am J Gastroenterol 1991; 86: 971-5.
26. Graham DY. Clarithromycin for treatment of Helicobacter pylon infections. Eur J Gastroenterol Hepatol 1995; 7(Suppl. 1): S55-8.
27. Malanoski GJ, Eliopoulos GM, Ferraro MJ, Moellering RC Jr. Effect of pH, variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis 1993; 12: 131-3.
28. Nagate T, Numata K, Hanada K, Kondo I. The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics. J Clin Gastroenterol 1990; 12(Suppl. 1): S135-8.
29. Hardy DJ, Hanson CW, Hensey DM, Beyer JM, Fernandes PB. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother 1988; 22: 631-6.
30. Thijs JC, Van Zwet AA, Moolenaar W, Oom JA, DeKorte H, Runhaar EA. Clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. Aliment Pharmacol Ther 1994; 8: 131-4.
31. Al-Assi MT, Genta RM, Karttunen TJ, Cole RA, Graham DY. Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth. Am J Gastroenterol 1995; 90: 403-5.
32. Hu FL. Comparison of acid and Helicobacter pylori in ulcerogenesis of duodenal ulcer disease. Chung Hua I Hsueh Tsa Chih 1993; 73: 217-9; 253.
33. Morgan D, Kraft W, Bender M, Pearson A. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. The Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universities. Gastroenterology 1988; 95: 1178-84.
34. Resende LM, Queiroz DM, Burbosa AJ, et al. Histology of the mucosa of gastric antrum and body before and after eradication of Helicobacter pylori. Braz J Med Biol Res 1993; 26: 1279-89.
35. Rocha GA, Queiroz DM, Mendes EN, de Carvalho AS, de Oliveira AM, de Moura SB. Serodiagnosis of Helicobarter pylori infection in children by an indirect immunofluorescence test. J Pediatr Gastroenterol Nutr 1993; 16: 247-51.
36. Xiao SD, Liu WZ, Xia DH, et al. The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori - a randomized double-blind placebo-controlled clinical trial. Hepato-Gastroenterology 1990; 37: 503-6.
37. Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990; 34: 1637-41.